Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
OBJECTIVES: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not require INR monitoring. This study evaluated the cost-effectiveness of dabigatran versus vitamin K antagonist...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2012-12-01
|
Series: | Swiss Medical Weekly |
Subjects: | |
Online Access: | https://www.smw.ch/index.php/smw/article/view/1805 |